BGV wraps up fourth fund

BioGeneration Ventures, an early-stage venture firm focused on European biopharma, has closed its fourth fund at $119 million.

To read this article, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to read this article and more for free.

Share this